Anteris Technologies Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMEUF research report →
Price Chart
About the company
Anteris Technologies Ltd. is a medical device company focused on structural heart solutions. The firm manufactures and commercializes ADAPT, an advanced regenerative tissue product.
- CEO
- Wayne Geoffrey Paterson
- IPO
- 2013
- HQ
- Toowong, QLD, AU
Get TickerSpark's AI analysis on AMEUF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $120.50M
- P/E
- -2.54
- PEG
- 0.18
- P/S
- 229.92
- P/B
- 2.37
- EV/EBITDA
- -3.09
- Div Yield
- 0.00%
- Gross Margin
- 72.55%
- Op Margin
- -4574.84%
- Net Margin
- -4482.38%
- ROE
- -99.78%
- ROIC
- -50.15%
Latest fiscal year · YoY change
- Revenue
- $4.37M+8.8%
- Gross Profit
- $2.05M-18.7%
- Op Income
- $-126,625,640
- Net Income
- $-123,263,368-83.1%
- EPS
- $-6.09-41.3%
- OCF Growth
- -92.4%
- FCF Growth
- -86.6%
- 52W High
- $15.53
- 52W Low
- $5.55
- 50D MA
- $7.00
- 200D MA
- $10.64
- Beta
- 0.75
- RSI (14)
- 37
- Avg Volume
- 2.18K
No earnings-call transcripts are available for AMEUF yet.
- Free Float
- 152.7%
- Shares Outstanding
- 21.14M
- Float Shares
- 32.29M
Our AMEUF coverage
Recent articles, reports, and earnings notes.
No research on AMEUF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMEUF report →Anteris to Present at September Healthcare Investor Conferences
globenewswire.com · Aug 31
Anteris Technologies Announces Results for the Second Quarter of 2026
globenewswire.com · Aug 11
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
globenewswire.com · Jun 8
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
globenewswire.com · May 13
Anteris Announces Results for the First Quarter of 2026
globenewswire.com · May 12
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
globenewswire.com · May 5
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
globenewswire.com · Apr 28
Anteris Reports 2025 Financial Results and Provides Corporate Update
globenewswire.com · Feb 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.